AstraZeneca PLC
NASDAQ:AZN

Watchlist Manager
AstraZeneca PLC Logo
AstraZeneca PLC
NASDAQ:AZN
Watchlist
Price: 65.35 USD 1.41% Market Closed
Market Cap: 202.6B USD
Have any thoughts about
AstraZeneca PLC?
Write Note

EV/EBIT
Enterprise Value to EBIT

253.5
Current
257.7
Median
16.8
Industry
Lower than median
Higher than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
253.5
=
Enterprise Value
2.1T GBX
/
EBIT
10.3B USD
All Countries
Close
EBIT Growth EV/EBIT to Growth
UK
AstraZeneca PLC
NASDAQ:AZN
Average EV/EBIT: 1 869
253.5
131%
1.9
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
52.3
211%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
21.8
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
14.9
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.4
675%
0
CH
Roche Holding AG
SIX:ROG
11.5
28%
0.4
CH
Novartis AG
SIX:NOVN
13
58%
0.2
US
Pfizer Inc
NYSE:PFE
15.8
68%
0.2
IE
E
Endo International PLC
LSE:0Y5F
592.2
N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
1.6
2-Years Forward
EV/EBIT
1.4
3-Years Forward
EV/EBIT
1.3

See Also

Discover More